Effect of a Practice-wide Anti-TNF Proactive Therapeutic Drug Monitoring Program on Outcomes in Pediatric Patients with Inflammatory Bowel Disease
Reports on the feasibility and effectiveness of translating proactive, antitumor necrosis factor (TNF) therapeutic drug monitoring (TDM) for inflammatory bowel disease into practice-wide quality improvement (QI) are lacking. The study aimed to determine whether a TDM QI program improved outcomes at a large academic pediatric gastroenterology practice. The primary outcome was sustained clinical remission. The adjusted risk of developing high titer anti-drug antibodies (ADAs) was lower in the post
